Thermal behavior and decomposition kinetics of rifampicin polymorphs under isothermal and non-isothermal conditions

Brazilian Journal of Pharmaceutical Sciences - Tập 46 Số 2 - Trang 343-351 - 2010
Ricardo Francisco Alves1, Thaís Vitória da Silva Reis2, Luis Carlos Cides da Silva1, Sı́lvia Storpirtis1, Lucildes Pita Mercuri3, Jivaldo do Rosário Matos1
1University of São Paulo
2Oswaldo Cruz Faculties
3Federal University of Sao Paulo#TAB#

Tóm tắt

The thermal behavior of two polymorphic forms of rifampicin was studied by DSC and TG/DTG. The thermoanalytical results clearly showed the differences between the two crystalline forms. Polymorph I was the most thermally stable form, the DSC curve showed no fusion for this species and the thermal decomposition process occurred around 245 ºC. The DSC curve of polymorph II showed two consecutive events, an endothermic event (Tpeak = 193.9 ºC) and one exothermic event (Tpeak = 209.4 ºC), due to a melting process followed by recrystallization, which was attributed to the conversion of form II to form I. Isothermal and non-isothermal thermogravimetric methods were used to determine the kinetic parameters of the thermal decomposition process. For non-isothermal experiments, the activation energy (Ea) was derived from the plot of Log β vs 1/T, yielding values for polymorph form I and II of 154 and 123 kJ mol-1, respectively. In the isothermal experiments, the Ea was obtained from the plot of lnt vs 1/T at a constant conversion level. The mean values found for form I and form II were 137 and 144 kJ mol-1, respectively.

Từ khóa


Tài liệu tham khảo

AGRAWAL S, 2004, Solid state characterization of rifampicin samples and its biopharmaceutic relevance, Eur. J. Pharm. Sci, 22, 127, 10.1016/j.ejps.2004.02.011

ARAÚJO A. A. S, 2003, Thermal analysis of the antiretroviral zidovudine (AZT) and evaluation of the compatibility with excipients used in solid dosage forms, Int. J. Pharm, 260, 303, 10.1016/S0378-5173(03)00288-6

BACCHI A, 1998, Comprehensive study on structure-activity relationships of rifamycins: Discussion of molecular and crystal structure and spectroscopic and spectroscopic and thermochemical properties of rifamycin, J. Med. Chem, 41, 2319, 10.1021/jm970791o

BUJNOWSKI K, 2003, Rifamycin antibiotics-new compounds and synthetic methods: Part 1: Study of the reaction of 3-formylrifamycin SV with primary alkylamines or ammonia, Tetrahedron, 59, 1885, 10.1016/S0040-4020(03)00184-4

CARVALHO W. S, 2007, Diagnóstico de resistência do Mycobacterium tuberculosis à rifampicina utilizando-se da reação em cadeia da polimerase, Rev. Bras. Ciênc. Farm, 43, 31, 10.1590/S1516-93322007000100004

CIDES L.C.D, 2006, Thermal behaviour, compatibility study and decomposition kinetics of glimepiride under isothermal and non-isotermal conditions, J. Therm. Anal. Calorim, 84, 441, 10.1007/s10973-005-7131-8

FORD J.L, 1989, 108

GIRON D, 1998, Contribution of thermal methods and related techniques to the rational development of pharmaceuticals-Part 1, Pharm. Sci. Technol. Today, 1, 191, 10.1016/S1461-5347(98)00046-7

GIRON D, 1998, Contribution of thermal methods and related techniques to the rational development of pharmaceuticals-Part 2, Pharm. Sci. Technol. Today, 6, 262, 10.1016/S1461-5347(98)00066-2

HENWOOD S.Q, 2000, Solubility and dissolution properties of generic rifampicin raw materials, Drug Dev. Ind. Pharm, 26, 403, 10.1081/DDC-100101246

MATOS J.R, 2009, Aspectos gerais relativos ao desenvolvimento farmacotécnico de medicamento: análise térmica aplicada a fármacos e medicamentos, 32

OZAWA T, 1965, A new method of analyzing thermogravimetric data, Bull. Chem. Soc. Jpn, 38, 1881, 10.1246/bcsj.38.1881

PANCHAGNULA R, 2004, Biopharmaceutic and pharmacokinetics aspects of variable bioavailability of rifampicin, Int. J. Pharm, 271, 1, 10.1016/j.ijpharm.2003.11.031

PARISE FILHO R, 2004, Thermoanalytical characterization of potentially schistosomicide polymeric derivatives, J. Therm. Anal. Calorim, 75, 487, 10.1023/B:JTAN.0000027137.43662.de

PELIZZA G, 1977, Polymorphism of rifampicin, Farmaco (Sci), 32, 471

ROUQUEROL J, 2007, Developments in nomenclature, 5, 21

SALTINI C, 2006, Chemotherapy and diagnosis of tuberculosis, Resp. Med, 100, 2085, 10.1016/j.rmed.2006.09.015

SINGH S, 2001, A critical review of probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem, Int. J. Pharm, 228, 5, 10.1016/S0378-5173(01)00754-2

VENKATARAM S, 1995, Differential scanning calorimetry as a quick scanning technique for solid state stability studies, Drug Dev. Ind. Pharm, 21, 847, 10.3109/03639049509026649

2006

2007, 5

ZHANG Y, 2005, The magic bullets and tuberculosis drug targets, Annu. Rev. Pharmacol. Toxicol, 45, 529, 10.1146/annurev.pharmtox.45.120403.100120